The Underlying Condition: Increasing Diversity in Clinical Trials
National Journal: February 20, 2014
John J. Castellani is president and CEO of the Pharmaceutical Research and Manufacturers of America, which represents the country’s leading biopharmaceutical research and biotechnology companies. (Courtesy photo)
Opinion: African-Americans, at 12 percent of the population, comprise only 5 percent of clinical-trial participants; the numbers for Hispanics are 16 percent and 1 percent. It’s time for that inequity to change, PhRMA’s CEO says.
When a patient picks up her prescription for rheumatoid arthritis, she knows it will enable her to hold her grandson with less pain. The heart-disease survivor takes his statin to avoid bypass surgery that could significantly impact his quality of life. Medical innovations have the power to change lives, as these examples demonstrate. Read More